Alterity Gets FDA Nod To Conduct Phase 2 Trial Of ATH434 In Multiple System Atrophy

Alterity Therapeutics Ltd. (ATHE), a company focused on neurodegenerative diseases, said on Tuesday that it has received FDA clearance to conduct a phase II clinical trial of ATH434 in Multiple System Atrophy.

Multiple System Atrophy or MSA, is a rare and highly debilitating Parkinsonian disorder.

The phase II clinical trial will explore the effect of ATH434 treatment on neuroimaging and protein biomarkers, such as excess brain iron and aggregating a-synuclein, which are important contributors to MSA pathology. The study is expected to enroll approximately 60 adult patients.

Alterity expects to open its first clinical trial site for enrolment next quarter (Q4, 2022).

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
United Airlines and Archer Aviation Inc. announced plans to launch the first commercial electric air taxi route in Chicago, between O'Hare International Airport or ORD and Vertiport Chicago. As part of their urban air mobility or UAM network buildout, both companies will utilize Archer's electric vertical takeoff and landing or eVTOL aircraft in the new route. Fort Wayne, Indiana-based Perfection Bakeries D/B/A Aunt Millie's is recalling 8 ct. packages of Our Family White Hot Dog Buns citing the possible presence of undeclared sesame, a known allergen, the U.S. Food and Drug Administration said. The product comes in a printed plastic package marked with "Our Family Hot Dog Buns 8 ct." on the top and has a blue twist tie. Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.
Follow RTT